Wednesday, July 15, 2020
Monday, July 6, 2020
The drug, STRO-002 is a combination antibody-drug conjugate, meaning it combines an antibody with chemo to deliver the medication directly to the cancer cell, hopefully eliminating some adverse side effects associated with off-targeting.
The results were presented at 2020 AACR Virtual Meeting of April 27-28.
Phase1 has been successfully completed which means that the toxic range of the medication has been established and now, Phase 2, will determine the recommended dose. OncLive conducted an interview with one of the lead investigators. Follow this link to the full article.